Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., Skene, A.M., Tan, M.H., Lefèbvre, P.J., Murray, G.D., Standl, E., Wilcox, R.G., Wilhelmsen, L., Betteridge, J., Birkeland, K., Golay, A., Heine, R.J., Korányi, L., Laakso, M., Mokán, M., Norkus, A., Pirags, V., Podar, T., Scheen, A., Scherbaum, W., Schernthaner, G., Schmitz, O., Skrha, J., Smith, U. and Taton, J. (2005) Secondary prevention of macrovas- cular events in patients with type 2 diabetes in the PRO- active Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial. Lancet, 366, 1279-1289. doi:10.1016/S0140-6736(05)67528-9

has been cited by the following article:

• TITLE: Skeletal muscle and whole body insulin resistance but not cardiac muscle insulin resistance could be improved by troglitazone therapy within 12 weeks in type-2 diabetes

  AUTHORS: Ikuo Yokoyama, Toshiyuki Moritan, Yusuke Inoue

  KEYWORDS: Insulin Resistance; Myocardial Insulin Resistance; Glucose Metabolism; Skeletal Muscle; Type II Diabetes Mellitus; 18F-FDG; PET

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.5 No.12A, December 31, 2012

  ABSTRACT: Background: Existence of myocardial insulin resistance (IR) has been reported in type II diabetics (T2- DM) and coronary artery disease (CAD). Improvement in heart and skeletal muscle IR after thiazolidinedione’s therapy was reported in T2DM and CAD. However effects of troglitazone therapy (TRO) on myocardial IR remain uncertain. To clarify heart and skeletal muscle and whole body IR in T2DM without CAD by TRO to clarify whether TRO would provide different results. Methods: We analyzed data on 15 T2DM patients who underwent dynamic PET with 18F-FDG under insulin clamping before and during TRO (200 mg/day) and 17 controls. Results: Whole body glucose disposal rate (WBGR mg/min/kg) in T2DM before TRO (3.41 ± 1.72) was significantly lower than in controls (9.76 ± 2.97, p